Q3 2018 Trends in Medtech Transactions Report
Locust Walk is a global life sciences transaction firm. Our integrated team-based approach across capabilities, geographies, and industry segments delivers the right products, the right partners, and the most attractive sources of capital to get the right deals done for biopharma and medtech companies.
Each quarter, Locust Walk deal team members compile key statistics and performance indicators on the latest medtech transactions. Our Q3 2018 Trends in Medtech Transactions Report applies the latest data to analyze current activities in the life sciences deal landscape.
In this quarter’s report you can find an overview and analysis of the following medtech activities:
- Key performance indicators for the medtech market
- Private financing activity and performance
- Deal activity for M&A
HERE’S A SUMMARY OF KEY FINDINGS:
- Steady pace of M&A deals in Q3 2018 of both publicly traded and privately-held targets
- Medtronic acquisition of Mazor Robotics ($1,640M)
- Stryker acquisition of K2M ($1,400M)
- Boston Scientific acquisition of Augmenix ($500M upfront + $100M milestones)
- Wright Medical acquisition of Cartiva ($435M)
- Boston Scientific acquisition of Claret Medical ($220M upfront + $50M milestone)
- Stryker acquisition of Invuity ($190M)
- Financings in the medtech sector continue to be sourced from a myriad of players
- Venture Capital, Corporate VCs, Strategics, Healthcare Systems, Payers, Sovereign Wealth Funds, Asset Management Firms, Family Offices, etc.
- IPO activity in Q3 focused on the aesthetics segment
- Establishment Labs, developer and manufacturer of silicone-filled breast and body shaping implants raised $66.9M (NASDAQ: ESTA)
- Ra Medical Systems, developer of excimer lasers designed for the treatment of dermatologic and cardiovascular diseases, raised $66.3M (NYSE: RMED)
- Stable US FDA regulatory environment, changes in Europe
- US FDA submission review times consistent with prior years, no significant backlog
- Evolving EU medical device regulations with the potential for increased clinical trial evidence requirements